中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 5
May  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(5): 934-939

Value of magnetic resonance imaging-proton density fat fraction in evaluating the degree and distribution characteristics of hepatic steatosis in patients with chronic hepatitis B virus infection

DOI: 10.12449/JCH240511
  • a.

    Department of Gastroenterology, Beijing Tsinghua Changgung Hospital，Tsinghua University，Beijing 102218，China

  • b.

    Department of Radiological Diagnosis，Beijing Tsinghua Changgung Hospital，Tsinghua University，Beijing 102218，China

Research funding:

Beijing Natural Science Foundation (7202240);

Tsinghua University Independent Research (2022PY002)

More Information
  • Corresponding author: HUANG Yuan， huangy9815@163.com （ORCID： 0000-0003-1392-4619）
  • Received Date: 2023-07-27
  • Accepted Date: 2023-09-05
  • Published Date: 2024-05-25
    Abstract
  •   Objective  To investigate the value of magnetic resonance imaging-proton density fat fraction （MRI-PDFF） in evaluating hepatic steatosis in patients with chronic hepatitis B virus （HBV） infection.  Methods  The patients， aged >16 years， who visited the outpatient service or were hospitalized in Beijing Tsinghua Changgung Hospital from January 2018 to December 2022 and were diagnosed with chronic HBV infection were enrolled， and all patients underwent MRI examination of the liver in our hospital. The patients were divided into groups based on the presence or absence of liver cirrhosis， and the consistency in PDFF between different hepatic segments was compared between groups. The Kappa consistency test and intraclass correlation coefficient （ICC） were used for consistency analysis.  Results  A total of 76 patients treated with nucleoside analogues were enrolled， among whom 23 （30.26%） had liver cirrhosis. For all patients， the simple arithmetic average of PDFF fluctuated between 1.49% and 30.93%. According to MRI-PDFF ≥5% as the diagnostic criterion for fatty liver disease， there were 29 patients （38.16%） with fatty liver disease among all patients. For all 76 patients， the simple arithmetic average of PDFF was lower than the weighted average of PDFF for the whole liver， and there was no significant difference between the simple arithmetic average of PDFF， the weighted average of PDFF， and the PDFF values of the left and right lobes of the liver （F=0.39， P=0.76）. The consistency test showed that the PDFF values of each hepatic segment and the left and right lobes of the liver had strong consistency with the weighted average and simple arithmetic average of PDFF， with an ICC of >0.75， but the consistency between the PDFF value of the right lobe and the weighted average of PDFF was higher than that between the PDFF value of the left lobe and the weighted average of PDFF. In the consistency test of differentiating fatty liver disease in patients with liver cirrhosis， there was poor consistency between the PDFF value of segment Ⅶ and the weighted average of PDFF （Kappa=0.39）， with moderate consistency for the left lobe and the Ⅰ， Ⅱ， Ⅲ， Ⅴ， Ⅵ， and Ⅷ segments. For the patients with liver cirrhosis， the lowest consistency was observed between the PDFF value of Ⅶ segment and the weighted average of PDFF for the whole liver， and the highest consistency was observed between the PDFF value of Ⅵ segment and the weighted average of PDFF for the whole liver. For the patients without liver cirrhosis， the lowest consistency was observed between the PDFF value of Ⅱ segment and the weighted average of PDFF for the whole liver， and the highest consistency was observed between the PDFF value of Ⅴ segment and the weighted average of PDFF for the whole liver.  Conclusion  MRI-PDFF is more comprehensive in evaluating hepatic steatosis in patients with chronic HBV infection， and for the patients with liver cirrhosis， there is poor consistency between the PDFF value of each segment and the weighted average of PDFF.

     

    • FullText(HTML)
    • References(20)
  • [1]
    KARLAS T, PETROFF D, SASSO M, et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP) technology for assessing steatosis[J]. J Hepatol, 2017, 66( 5): 1022- 1030. DOI: 10.1016/j.jhep.2016.12.022.
    [2]
    SINGH S, ALLEN AM, WANG Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies[J]. Clin Gastroenterol Hepatol, 2015, 13( 4): 643- 654. e1-9; quize39-40. DOI: 10.1016/j.cgh.2014.04.014.
    [3]
    LI J, YANG HI, YEH ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B[J]. J Infect Dis, 2021, 224( 2): 294- 302. DOI: 10.1093/infdis/jiaa739.
    [4]
    REEDER SB, CRUITE I, HAMILTON G, et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy[J]. J Magn Reson Imaging, 2011, 34( 4): 729- 749. DOI: 10.1002/jmri.22775.
    [5]
    LE TA, CHEN J, CHANG C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial[J]. Hepatology, 2012, 56( 3): 922- 932. DOI: 10.1002/hep.25731.
    [6]
    LOOMBA R, SIRLIN CB, ANG B, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial(MOZART trial)[J]. Hepatology, 2015, 61( 4): 1239- 1250. DOI: 10.1002/hep.27647.
    [7]
    Chinese Medical Association, Chinese Society of Infectious Disease. Guidelines for the prevention and treatment of chronic hepatitis B(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
    [8]
    CAUSSY C, ALQUIRAISH MH, NGUYEN P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis[J]. Hepatology, 2018, 67( 4): 1348- 1359. DOI: 10.1002/hep.29639.
    [9]
    MISE Y, SATOU S, SHINDOH J, et al. Three-dimensional volumetry in 107 normal livers reveals clinically relevant inter-segment variation in size[J]. HPB, 2014, 16( 5): 439- 447. DOI: 10.1111/hpb.12157.
    [10]
    TOKUSHIGE K, IKEJIMA K, ONO M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020[J]. J Gastroenterol, 2021, 56( 11): 951- 963. DOI: 10.1007/s00535-021-01796-x.
    [11]
    TOKUSHIGE K, IKEJIMA K, ONO M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020[J]. J Gastroenterol, 2021, 56( 11): 951- 963. DOI: 10.1007/s00535-021-01796-x.
    [12]
    PARK CC, NGUYEN P, HERNANDEZ C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152( 3): 598- 607. e 2. DOI: 10.1053/j.gastro.2016.10.026.
    [13]
    HERNANDO D, SHARMA SD, ALIYARI GHASABEH M, et al. Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom[J]. Magn Reson Med, 2017, 77( 4): 1516- 1524. DOI: 10.1002/mrm.26228.
    [14]
    VU KN, GILBERT G, CHALUT M, et al. MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes[J]. J Magn Reson Imaging, 2016, 43( 5): 1090- 1099. DOI: 10.1002/jmri.25083.
    [15]
    BONEKAMP S, TANG A, MASHHOOD A, et al. Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease[J]. J Magn Reson Imaging, 2014, 39( 6): 1525- 1532. DOI: 10.1002/jmri.24321.
    [16]
    KANG BK, KIM M, SONG SY, et al. Feasibility of modified Dixon MRI techniques for hepatic fat quantification in hepatic disorders: Validation with MRS and histology[J]. Br J Radiol, 2018, 91( 1089): 20170378. DOI: 10.1259/bjr.20170378.
    [17]
    ANAVI S, MADAR Z, TIROSH O. Non-alcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers[J]. Redox Biol, 2017, 13: 386- 392. DOI: 10.1016/j.redox.2017.06.008.
    [18]
    LI YT, CERCUEIL JP, YUAN J, et al. Liver intravoxel incoherent motion(IVIM) magnetic resonance imaging: A comprehensive review of published data on normal values and applications for fibrosis and tumor evaluation[J]. Quant Imaging Med Surg, 2017, 7( 1): 59- 78. DOI: 10.21037/qims.2017.02.03.
    [19]
    BOUDINAUD C, ABERGEL A, JOUBERT-ZAKEYH J, et al. Quantification of steatosis in alcoholic and nonalcoholic fatty liver disease: Evaluation of four MR techniques versus biopsy[J]. Eur J Radiol, 2019, 118: 169- 174. DOI: 10.1016/j.ejrad.2019.07.025.
    [20]
    IDILMAN IS, ANIKTAR H, IDILMAN R, et al. Hepatic steatosis: Quantification by proton density fat fraction with MR imaging versus liver biopsy[J]. Radiology, 2013, 267( 3): 767- 775. DOI: 10.1148/radiol.13121360.
    • Relative Articles

  • Relative Articles

    [1]Longlong LUO, Lifei WANG, Guojing XING, Ying ZHENG, Lixia LU, Chuyi LI, Bin LI, Jun MA, Xiaohui YU, Jiucong ZHANG. Mechanism of action of follicular helper T cells in autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(7): 1466-1469. doi: 10.12449/JCH240727
    [2]Wendi DONG, Hairong ZHANG, Rui LI, Yuyan ZHANG, Jie ZHU. Role of regulatory T/T helper 17 cells in the pathogenesis of autoimmune hepatitis and related therapeutic targets[J]. Journal of Clinical Hepatology, 2021, 37(10): 2456-2460. doi: 10.3969/j.issn.1001-5256.2021.10.042
    [3]Guangjun TANG, Jing YOU, Huai'e LIU, Yujuan PENG. Role of T helper 17 cell/regulatory T cell imbalance in the progression of HBV-related liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(2): 414-418. doi: 10.3969/j.issn.1001-5256.2021.02.035
    [4]YANG JingShu, LI Ning. Research advances in T helper 17 cells in chronic inflammatory liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2808-2810. doi: 10.3969/j.issn.1001-5256.2020.12.034
    [5]Pan Jing, Pan WenTing, Wu LiHui. Expression and significance of Th22 cells and its functional factor interleukin-22 in mice with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1745-1749. doi: 10.3969/j.issn.1001-5256.2018.08.030
    [6]Chen Bin, Zhang Tao, Zhu WenFang, Peng Jie, Zhang QianQian, Li YunFang, Ding XiuLi. Effect of the warming and heat-clearing method on the percentage of regulatory T lymphocytes/T helper 17 cells in rats with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2018, 34(12): 2642-2647. doi: 10.3969/j.issn.1001-5256.2018.12.026
    [7]Gao WeiHua, Ge KuanXue, Xiang XiaoXing. Association of Th17 cells, regulatory T cells, and their imbalance with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(6): 1347-1350. doi: 10.3969/j.issn.1001-5256.2018.06.046
    [8]Wang Yan, Huang YouYing, Ma Yan, Guo Feng, Wang XiaoBo, Wang XiaoZhong. Expression features of follicular helper T cells in peripheral blood in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(1): 58-62. doi: 10.3969/j.issn.1001-5256.2018.01.012
    [9]Ge KuanXue, Gao WeiHua, Xiang XiaoXing. Association of regulatory T cells, T helper 17 cells, and change in their balance with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1573-1576. doi: 10.3969/j.issn.1001-5256.2018.07.045
    [10]Guo FeiBo, Wu JunZhu, Ai LiMing, Song Ying. Clinical significance of Th17/Treg and associated cytokines in peripheral blood in chronic hepatitis C patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 479-484. doi: 10.3969/j.issn.1001-5256.2017.03.017
    [11]Zhang FeiFei, Chen Hui, Lyu Jun. Role of T-helper cell 17 in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(8): 1626-1629. doi: 10.3969/j.issn.1001-5256.2016.08.046
    [12]He JunNan, Zhao ShouSong. Research advances in association between regulatory T cells and hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2016, 32(2): 361-365. doi: 10.3969/j.issn.1001-5256.2016.02.036
    [13]Li Hong, Cao ShanShan, Zhao YaNan, Yang ZhongXin. Influence of intestinal endotoxemia on Treg/Th17 imbalance in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(10): 1878-1882. doi: 10.3969/j.issn.1001-5256.2016.10.011
    [14]Ji LongShan, Sun XueHua, Zhou ZhenHua, Zhang Xin, Gao YaTing, Gao YueQiu, Li Man. Role of follicular helper T cells in development and progression of liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(6): 1230-1234. doi: 10.3969/j.issn.1001-5256.2016.06.050
    [15]Zhou Yan, Jing Xiang, Zhu ZhengYan. Roles of regulatory T cells and T-helper cells in hepatitis B virus-related liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(10): 1994-1997. doi: 10.3969/j.issn.1001-5256.2016.10.040
    [16]Cheng Ping, Xue BoYu. Research progress in Treg/Th17 imbalance in persistent HBV infection[J]. Journal of Clinical Hepatology, 2015, 31(4): 603-606. doi: 10.3969/j.issn.1001-5256.2015.04.031
    [17]Huang JinFa, Xu Tao, Pan XingNan, Lai XiaoHuan, Zheng LianQiu, Huang ZhiJie. Measurement of peripheral blood Treg,Tr1,and Th17 cells in patients with chronic hepatitis B and its clinical significance[J]. Journal of Clinical Hepatology, 2015, 31(4): 551-555. doi: 10.3969/j.issn.1001-5256.2015.04.018
    [18]Gao Jun, Chen Gong, Lu: Long. Protective role and immunoregulatory effect of CXCR3 in hepatic ischemia- reperfusion injury[J]. Journal of Clinical Hepatology, 2014, 30(8): 790-794. doi: 10.3969/j.issn.1001-5256.2014.08.023
    [19]Chen HuiJuan, Zhao ShouSong. Recent insights into the roles of regulatory T cells in viral hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(11): 868-871.
    [20]Zhou DongFang, Hu ChaoGang, Zhou JunYing. NK cells and hepatitis C[J]. Journal of Clinical Hepatology, 2011, 27(12): 1341-1344.
    • Supplements(0)
    • Cited By
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-040255075100125
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 2.6 %FULLTEXT: 2.6 %META: 95.4 %META: 95.4 %PDF: 2.0 %PDF: 2.0 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 3.6 %其他: 3.6 %其他: 0.9 %其他: 0.9 %Kao-sung: 0.4 %Kao-sung: 0.4 %Shirayamamachi: 0.1 %Shirayamamachi: 0.1 %Tiruchi: 0.1 %Tiruchi: 0.1 %上海: 3.0 %上海: 3.0 %东京: 0.1 %东京: 0.1 %东莞: 0.1 %东莞: 0.1 %临汾: 0.1 %临汾: 0.1 %佛山: 0.4 %佛山: 0.4 %兰州: 0.2 %兰州: 0.2 %北京: 2.5 %北京: 2.5 %华盛顿州: 0.1 %华盛顿州: 0.1 %南京: 0.9 %南京: 0.9 %南宁: 0.7 %南宁: 0.7 %南昌: 0.2 %南昌: 0.2 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %厦门: 0.2 %厦门: 0.2 %台北: 0.4 %台北: 0.4 %合肥: 0.1 %合肥: 0.1 %周口: 0.5 %周口: 0.5 %咸阳: 0.1 %咸阳: 0.1 %哥伦布: 0.1 %哥伦布: 0.1 %嘉兴: 0.2 %嘉兴: 0.2 %圣安东尼奥: 0.1 %圣安东尼奥: 0.1 %夏延: 0.1 %夏延: 0.1 %天津: 0.8 %天津: 0.8 %宁波: 0.1 %宁波: 0.1 %宜春: 0.1 %宜春: 0.1 %山景城: 0.2 %山景城: 0.2 %常德: 0.3 %常德: 0.3 %广州: 0.6 %广州: 0.6 %廊坊: 0.1 %廊坊: 0.1 %延边: 0.2 %延边: 0.2 %张家口: 1.6 %张家口: 1.6 %徐州: 0.3 %徐州: 0.3 %得梅因: 0.1 %得梅因: 0.1 %惠州: 0.2 %惠州: 0.2 %成都: 0.3 %成都: 0.3 %扬州: 0.2 %扬州: 0.2 %新余: 0.1 %新余: 0.1 %无锡: 0.3 %无锡: 0.3 %昆明: 0.3 %昆明: 0.3 %朝阳: 0.1 %朝阳: 0.1 %杭州: 0.8 %杭州: 0.8 %桂林: 0.2 %桂林: 0.2 %武汉: 0.1 %武汉: 0.1 %汕头: 0.1 %汕头: 0.1 %沈阳: 0.6 %沈阳: 0.6 %泸州: 0.1 %泸州: 0.1 %洛阳: 0.3 %洛阳: 0.3 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.3 %海得拉巴: 0.3 %淄博: 0.1 %淄博: 0.1 %深圳: 0.2 %深圳: 0.2 %湘潭: 0.1 %湘潭: 0.1 %滁州: 0.1 %滁州: 0.1 %漯河: 0.2 %漯河: 0.2 %珠海: 0.2 %珠海: 0.2 %班加罗尔: 0.1 %班加罗尔: 0.1 %白山: 0.1 %白山: 0.1 %石家庄: 0.1 %石家庄: 0.1 %福州: 0.1 %福州: 0.1 %科泽科德: 0.1 %科泽科德: 0.1 %秦皇岛: 0.1 %秦皇岛: 0.1 %绵阳: 0.1 %绵阳: 0.1 %自贡: 0.1 %自贡: 0.1 %芒廷维尤: 48.1 %芒廷维尤: 48.1 %芝加哥: 1.4 %芝加哥: 1.4 %苏州: 0.3 %苏州: 0.3 %莆田: 0.2 %莆田: 0.2 %葫芦岛: 0.1 %葫芦岛: 0.1 %蚌埠: 0.2 %蚌埠: 0.2 %衡水: 0.3 %衡水: 0.3 %衡阳: 0.1 %衡阳: 0.1 %西宁: 6.7 %西宁: 6.7 %西安: 0.6 %西安: 0.6 %许昌: 0.1 %许昌: 0.1 %诺沃克: 0.2 %诺沃克: 0.2 %贵阳: 0.4 %贵阳: 0.4 %运城: 0.5 %运城: 0.5 %遵义: 0.1 %遵义: 0.1 %邯郸: 0.2 %邯郸: 0.2 %郑州: 1.2 %郑州: 1.2 %重庆: 0.4 %重庆: 0.4 %金奈: 0.1 %金奈: 0.1 %铁岭: 0.1 %铁岭: 0.1 %长春: 8.4 %长春: 8.4 %长沙: 1.9 %长沙: 1.9 %长治: 0.2 %长治: 0.2 %阜新: 0.1 %阜新: 0.1 %青岛: 0.9 %青岛: 0.9 %香港: 0.5 %香港: 0.5 %其他其他Kao-sungShirayamamachiTiruchi上海东京东莞临汾佛山兰州北京华盛顿州南京南宁南昌卡纳塔克厦门台北合肥周口咸阳哥伦布嘉兴圣安东尼奥夏延天津宁波宜春山景城常德广州廊坊延边张家口徐州得梅因惠州成都扬州新余无锡昆明朝阳杭州桂林武汉汕头沈阳泸州洛阳济南海得拉巴淄博深圳湘潭滁州漯河珠海班加罗尔白山石家庄福州科泽科德秦皇岛绵阳自贡芒廷维尤芝加哥苏州莆田葫芦岛蚌埠衡水衡阳西宁西安许昌诺沃克贵阳运城遵义邯郸郑州重庆金奈铁岭长春长沙长治阜新青岛香港

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (707) PDF downloads(52) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2389]YesterdayPV[5285]TodayIP[2122]TodayPV[4657]Online[45]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return